This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ursin, G. Articles by Greendale, G. A. Search for Related Content PubMed PubMed Citation Articles by Ursin, G. Articles by Greendale, G. A. Social Bookmarking                            What's this?

Post-Treatment Change in Serum Estrone Predicts Mammographic Percent Density Changes in Women Who Received Combination Estrogen and Progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial

From the Department of Preventive Medicine/Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine; David Geffen School of Medicine at University of California, Division of Geriatric Medicine, Los Angeles, CA; Department of Nutrition, University of Oslo, Norway; and Wake Forest University School of Medicine, Department of Public Health Sciences, Winston-Salem, NC

Address correspondence to Giske Ursin, MD, PhD, Department of Preventive Medicine, Norris Comprehensive Cancer Center, Room 4407, USC Keck School of Medicine, 1441 Eastlake Ave, Los Angeles, CA 90089; e-mail: gursin{at}usc.edu

PURPOSE: Postmenopausal estrogen and progestin therapy (EPT) increases mammographic percent density and breast cancer risk substantially more than does estrogen therapy alone. We determined whether increases in serum estrone as a function of treatment predict increases in mammographic percent density.

METHODS: We measured mammographic percent density and serum estrone levels in participants in the Postmenopausal Estrogen/Progestin Interventions Trial who were randomly assigned to receive conjugated equine estrogens (CEE) 0.625 mg/d; CEE and medroxyprogesterone acetate (MPA) 10 mg on days 1 to 12 per 28-day cycle; CEE and MPA 2.5 mg/d; or CEE and micronized progesterone (MP) 200 mg on days 1 to 12 per 28-day cycle. We used linear regression to determine whether serum estrone changes predicted mammographic percent density changes from baseline to 1 year.

RESULTS: Mammographic percent density increased with increasing change in estrone level in the EPT groups, but not in the CEE group. Combined, the mammographic percent density in the three EPT groups demonstrated an absolute increase of 2.95% per 100 pg/mL increase in serum estrone level (P = .0003). The absolute increases were 4.09% (P = .0018) in the CEE + MPA continuous group, 2.79% (P = .0292) in the CEE + MPA cyclical group, and 1.40% (P = .36) in the CEE + MP group, but the differences among the EPT groups were not statistically significant.

CONCLUSION: Greater increase in serum estrone level as a function of treatment is a significant predictor of increase in mammographic percent density in women randomly assigned to the combination of estrogen and progestin.

Supported by grant funding from the National Cancer Institute, R-01 CA 77708, and by P30CA14089 (M.C.P.).

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. J. Crandall, A. K. Aragaki, R. T. Chlebowski, A. McTiernan, G. Anderson, S. L. Hendrix, B. B. Cochrane, L. H. Kuller, and J. A. Cauley New-Onset Breast Tenderness After Initiation of Estrogen Plus Progestin Therapy and Breast Cancer Risk Arch Intern Med, October 12, 2009; 169(18): 1684 - 1691. [Abstract] [Full Text] [PDF]

				C. J. Crandall, M. Guan, G. A. Laughlin, G. A. Ursin, F. Z. Stanczyk, S. A. Ingles, E. Barrett-Connor, and G. A. Greendale Increases in Serum Estrone Sulfate Level Are Associated with Increased Mammographic Density during Menopausal Hormone Therapy Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1674 - 1681. [Abstract] [Full Text] [PDF]

				J. N. Weitzel, S. S. Buys, W. H. Sherman, A. M. Daniels, G. Ursin, J. R. Daniels, D. J. MacDonald, K. R. Blazer, M. C. Pike, and D. V. Spicer Reduced Mammographic Density with Use of a Gonadotropin-Releasing Hormone Agonist-Based Chemoprevention Regimen in BRCA1 Carriers Clin. Cancer Res., January 15, 2007; 13(2): 654 - 658. [Abstract] [Full Text] [PDF]

				J. V. Lacey Jr., L. A. Brinton, M. F. Leitzmann, T. Mouw, A. Hollenbeck, A. Schatzkin, and P. Hartge Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst, October 4, 2006; 98(19): 1397 - 1405. [Abstract] [Full Text] [PDF]

				C. J. Crandall, A. Karlamangla, M.-H. Huang, G. Ursin, M. Guan, and G. A. Greendale Association of New-Onset Breast Discomfort With an Increase in Mammographic Density During Hormone Therapy Arch Intern Med, August 14, 2006; 166(15): 1578 - 1584. [Abstract] [Full Text] [PDF]

				M. R. Palomares, J. R.B. Machia, C. D. Lehman, J. R. Daling, and A. McTiernan Mammographic density correlation with gail model breast cancer risk estimates and component risk factors. Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1324 - 1330. [Abstract] [Full Text] [PDF]

				A. McTiernan, C. F. Martin, J. D. Peck, A. K. Aragaki, R. T. Chlebowski, E. D. Pisano, C. Y. Wang, R. L. Brunner, K. C. Johnson, J. E. Manson, et al. Estrogen-Plus-Progestin Use and Mammographic Density in Postmenopausal Women: Women's Health Initiative Randomized Trial J Natl Cancer Inst, September 21, 2005; 97(18): 1366 - 1376. [Abstract] [Full Text] [PDF]

				J. R. Cerhan, T. A. Sellers, C. A. Janney, V. S. Pankratz, K. R. Brandt, and C. M. Vachon Prenatal and Perinatal Correlates of Adult Mammographic Breast Density Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1502 - 1508. [Abstract] [Full Text] [PDF]